Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy device which leverages the real-time tissue characterization capability of its radio-frequency (RF) spectroscopy technology.
These first in-man cases were completed by Dr. Noemi Weissenberg, Radiologist, at the Meir Medical Center in Kfar Saba, Israel. Utilizing miniaturized sensors located on a core needle, Smart Biopsy generated, in real time, electrical parameters of the sampled tissue. These electrical parameters will be compared to histopathologic findings in order to provide additional value with regard to improving diagnosis and read-out.
The Smart Biopsy device represents a significant breakthrough in Dune Medical’s quest to offer real-time, multi-cancer, diagnostic and treatment applications. Dune Medical’s RF Spectroscopy and its miniaturized sensor technology provide the most accurate interpretation of electrical parameters which correlate to tissue type, and most importantly, to the differentiation between cancer and healthy tissue. Identifying tissue properties during the biopsy procedure enables the physician to enhance their diagnostic capability beyond just image guidance, potentially preventing patients the anxiety of an underdiagnosis or overdiagnosis.
The development of Smart Biopsy was supported by the prestigious European Union Horizon 2020 research grant that Dune Medical received in 2016. The device and its technology were recently featured in an article by Medical Device and Diagnostic Industry (MD+DI).
Dune Medical Devices CEO Lori Chmura is enthusiastic about the progress made. “The in-man phase is the continuation of a broader and more comprehensive clinical trial aimed at definitive tissue characterization in the breast, Dunes first application. The collective works will be published later this year as a revolutionary solution for enhancing accuracy in biopsy diagnoses and guide future development of RF Spectroscopy across the oncology spectrum. We’re thrilled to have met this important milestone in our strategy to offer multi-cancer applications.”